Clinical trials: Hodgkin Lymphoma
Lymphoma, Non-Hodgkin's
Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to evaluate the mechanism(s) of action of galiximab in subjects with previously untreated follicular NHL.
- Trial name
- NCT00651443
- Testing
- Galiximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Biogen
Extranodal NK/T-cell Lymphoma
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
This program is intended to provide access to sugemalimab for participants with R/R ENKTL, after their disease failed to respond to prior treatment regimen(s), preceding marketing authorization by the local regulatory agency.
- Trial name
- NCT05131438
- Testing
- sugemalimab
- Where
- United States
- Sponsor
- EQRx International, Inc.
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02851589
- Testing
- PCAR-019 (anti-CD19 CAR-T cells)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
MB-CART20.1 Lymphoma
This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.
- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
- Trial name
- NCT03664635
- Testing
- MB-CART20.1
- Where
- 2 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Miltenyi Biomedicine GmbH
Relapsed or Refractory Classical Hodgkin Lymphoma
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
- Trial name
- NCT05216835
- Testing
- Sabestomig (AZD7789)
- Where
- 14 sites in United States, Canada and 5 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Lymphoma, Mantle-Cell
Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants
The purpose of the study (retrospective and prospective) is to describe participant and disease characteristics and treatment pattern of Bortezomib treated mantle cell lymphoma (MCL) participants in China.
- Trial name
- NCT03053024
- Where
- 9 sites in China
- Volunteers
- 54 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Cutaneous T-Cell Lymphoma, Leukemia-Lymphoma, Adult T-Cell
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
This study will assess the safety, efficacy and pharmacokinetics of oral LBH589 in Japanese adult patients with refractory cutaneous T-Cell Lymphoma and adult T-cell leukemia/lymphoma.
- Trial name
- NCT00699296
- Testing
- Panobinostat (LBH589)
- Where
- 7 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Breast Cancer
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy…
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML)
- Trial name
- NCT02391480
- Testing
- ABBV-075, Venetoclax
- Where
- 10 sites in United States
- Volunteers
- 128 people
- Sponsor
- AbbVie
Follicular Lymphoma
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel…
- Trial name
- NCT06794268
- Testing
- Lisocabtagene maraleucel
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Lymphoma, T-Cell
MB-105 in Patients With CD5 Positive T-cell Lymphoma
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
- Trial name
- NCT06534060
- Testing
- Genetic: MB-105
- Where
- 12 sites in United States
- Volunteers
- 46 people
- Sponsor
- March Biosciences Inc
Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib/II, open-label, multicenter, non-randomized, dose-escalation study will evaluate the safety, efficacy, and pharmacokinetics of obinutuzumab in combination with idasanutlin and venetoclax in participants with R/R FL…
- Trial name
- NCT03135262
- Testing
- Idasanutlin, Obinutuzumab, Venetoclax
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, B-Cell
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of relapsed or refractory B-cell Non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00998946
- Testing
- Pralatrexate, Vitamin B12, Folic Acid
- Where
- 11 sites in United States
- Volunteers
- 29 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Solid Tumor, Non-Hodgkin Lymphoma
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
This is a Phase 1, open-label, dose-escalation, single-center study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/ refractory non-Hodgkin lymphoma.
- Trial name
- NCT03802955
- Testing
- ADG106
- Where
- 2 sites in China
- Volunteers
- 62 people
- Sponsor
- Adagene (Suzhou) Limited
Lymphoma, T-Cell, Cutaneous
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
The purpose of this research study is to evaluate how effective ONTAK is in the treatment of cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein called CD25 on the cancer cells makes a…
- Trial name
- NCT00211198
- Testing
- ONTAK (denileukin difitox, DAB389IL-2)
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Eisai Inc.
B-cell Acute Lymphoblastic Leukemia
Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk
Previous findings have shown that a biomarker comprised of the three microRNAs (miRs) miR-451, miR-151-5p and miR-1290 can independently predict precursor B-cell acute lymphoblastic leukemia (B- ALL) patients' risk for relapse…
- Trial name
- NCT03000335
- Where
- 2 sites in Israel
- Volunteers
- 65 people
- Sponsor
- Curewize Health Ltd.
Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
The purpose of this phase 1 study is to evaluate the safety and anti-tumor activity of Loncastuximab Tesirine (ADCT-402) and Durvalumab in participants with Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or…
- Conditions
- Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT03685344
- Testing
- Loncastuximab Tesirine and Durvalumab
- Where
- 14 sites in United States, Spain
- Volunteers
- 13 people
- Sponsor
- ADC Therapeutics S.A.
B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL)
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who…
- Conditions
- B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
- Trial name
- SOUNDTRACK-B (NCT06526793)
- Testing
- Surovatamig
- Where
- 94 sites in United States, Australia and 14 more
- Volunteers
- 270 people
- Sponsor
- AstraZeneca
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood.
- Conditions
- Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy
- Trial name
- IMAGINE (NCT05138458)
- Testing
- MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Myeloid Therapeutics
Relapsed or Refractory Diffuse Large B-cell Lymphoma
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
This is an open,single-arm,multicenter phase II clinical study to evaluate the efficacy and safety of BEBT-908 for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT06074107
- Testing
- BEBT-908 for injection
- Where
- China
- Volunteers
- 128 people
- Sponsor
- BeBetter Med Inc
Hodgkin's Lymphoma
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
The primary objective was to provide drug to ongoing patients who were receiving panobinostat and to characterize the safety and tolerability of panobinostat in patients with HL after achieving a complete response following…
- Trial name
- PATH (NCT01034163)
- Testing
- Panobinostat
- Where
- 35 sites in United States, Australia and 12 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.